onc brain

All studies · 128

• New 🌰 Prostate · 2026-08-29
  PROTEUS
  5-yr BCR-FS 44%, MFS 71%, CSS 92% at 60-mo median follow-up in a high-risk cohort.
• New 🌰 Prostate · 2026-08-27 ASTRO Annual Meeting 2025
  MARCAP Consortium
  IPD meta-analysis, 10,853 pts: ADT added to RT improved MFS HR 0.83 and OS HR 0.86; dose escalation improved bRFS only.
• New 🌀 GI Lower · 2026-08-24
  STAR-TREC
  12-mo TME-free survival 78.5% with LCCRT vs 60.6% with SCRT, HR 1.90 (1.29-2.81), in mrT1-T3bN0 rectal cancer.
• New 🌰 Prostate · 2026-08-21
  Focal Ablation vs IMRT Toxicity (SEER-Medicare)
  GI toxicity favored focal therapy at 24mo (11.0% vs 21.5%, OR 0.45) but GU toxicity favored IMRT (41.7% vs 29.3%, OR 1.69).
• New 🌰 Prostate · 2026-08-14
  NRG-GU005
  3yr DFS 88.6% SBRT vs 92.1% MH-IMRT, superiority rejected (adjusted HR 1.40, 0.91-2.13); bowel and GU toxicity favored SBRT.
• New 🌰 Prostate · 2026-08-13
  Testosterone recovery post-ADT discontinuation (podcast review)
  Review of two datasets: 25% of real-world pts recovered T within 12mo; 54% relugolix vs 3% leuprolide at 90d in HERO.
• New 🎀 Breast · 2026-08-13
  Moderately hypofractionated partial breast reirradiation
  40Gy/15fx PBI re-RT after second lumpectomy: 3yr LR-FS, DR-FS and OS all 86%, no grade 3+ late events (N=11).
• New 🎀 Breast · 2026-08-12
  NSABP B-35 margin-width analysis
  10yr IBTR 5.6% vs 4.0% at 1mm cutoff (abs diff 1.6%), 5.3% vs 3.8% at 2mm (abs diff 1.5%).
• New 🎀 Breast · 2026-08-12
  Cardiac Risk After Heart-Sparing Breast Radiotherapy
  Max LAD ≥12 Gy EQD2: sHR 1.81 (1.04-3.16) for cardiac events; mean heart dose ≥2 Gy null (P=.99), 2223 left-sided pts.
• New ⚠️ Safety / Regulatory · 2026-08-10 ASCO Genitourinary Cancers Symposium 2022
  Organs at Risk Radiation Dose Constraints: 2025 Update
  SFRO 2025 OAR dose-constraint update: normofractionated, moderate hypofractionated and ablative tables across skull base, H&N, lung, breast, oesophagus, liver.
• New 🌰 Prostate · 2026-08-10 ASCO Genitourinary Cancers Symposium 2022
  HERO
  90-day testosterone recovery to ≥280 ng/dL 53.9% with relugolix vs 3.2% with leuprolide after 48wk ADT.
• New 🟡 Hepatobiliary · 2026-08-08
  BEACON-HCC
  New North American HCC allocation framework; expert decisions 96.6% concordant with BEACON vs 72.4% with BCLC 2025 across 29 cases.
• New 🌰 Prostate · 2026-08-07
  PSMA PET Natural History Study in PSMA-Positive BCR
  Baseline data on first 130 pts: most BCR men with PSADT >9-12mo still have PSMA PET findings once PSA exceeds 5.
• New 🌰 Prostate · 2026-08-07
  USPCC 2026 Point-Counterpoint: PSMA PET Response Assessment in APMR
  High vs low δ-percent SUVmax carried HR 5.03 (1.17-21.65) for OS; δ-absolute SUVmax HR 9.31 (1.81-47.87).
• New 🌀 GI Lower · 2026-08-07
  STELLAR
  3yr DFS 64.5% v 62.3% (HR 0.883, NI margin 1.43, P<.001 NI): 5x5Gy then CAPOX non-inferior to 50Gy/25f CRT in LARC.
• New 🌀 GI Lower · 2026-08-07
  TNTCRT
  3-year DFS 74.8% v 66.0%, HR 0.674, for doublet CAPOX bracketing long-course chemoradiation vs conventional nCRT in high-risk LARC.
• New 🌀 GI Lower · 2026-08-01
  SIB-CRT vs Standard CRT for LARC (NCT02195141)
  9yr LC 87.1% vs 70.1% (HR 0.40, P=0.038) and OS 74.3% vs 48.9% (HR 0.43) favoring SIB dose escalation.
• New 💧 Bladder · 2026-07-31
  Dose-Escalated RT for Muscle-Invasive Bladder Cancer
  2yr invasive local recurrence 5.5% vs 27.5% with SIB dose escalation, adjusted SHR 0.20 (0.05-0.89), p=0.035; no OS or MFS difference.
• New 🫁 Thoracic / Lung · 2026-07-31
  Proactive Immune Cell Sparing SBRT (NCT04273893)
  ALC reduction 13.4% (5.3%) less with immune-sparing planning across all timepoints (95% CI 2.8-24.0, p=0.01) in early-stage lung SBRT.
• New 🫘 Kidney · 2026-07-31
  IROCK Contouring Guidelines (RCC SABR)
  First international consensus contouring atlas for RCC SABR: median DSC 0.85 across 16 experts, 4 scenario-specific iGTV statements.
• New 🌰 Prostate · 2026-07-31
  GÖTEBORG-1
  25yr PC-specific survival 94% on active surveillance, but failure-free survival fell to 68% at 22yr.
• New 🌰 Prostate · 2026-07-31
  POSEIDON
  OS HR 0·87 (0·76–1·01), p=0·06 for adding hormone therapy to PORT; benefit only above pre-PORT PSA 0·5 ng/mL.
• New 🚀 Practice-changing 🎀 Breast · 2026-07-29
  DBCG Skagen Trial 1
  3yr lymphedema 8.0% (40Gy/15fx) vs 9.4% (50Gy/25fx), OR 0.84 (0.62-1.14), noninferior; no recurrence or mortality differences at 8yr.
• New 🌰 Prostate · 2026-07-26
  PACE-B
  5-yr PROMs: leak-free 64% (164/258) SBRT vs 69% (172/249) CRT, p=0.19; no domain differed significantly.
• New 🌰 Prostate · 2026-07-22
  ProtecT (cribriform morphology secondary analysis)
  Secondary analysis: cribriform-negative disease (87% of reviewed cohort) got no significant 15-yr metastasis reduction from early radical treatment vs monitoring.
• New 🌰 Prostate · 2026-07-22
  ESTRO Prostate SBRT Consensus Recommendations
  Delphi: 36.25 Gy/5 fx standard, 100% vote against elective pelvic nodal RT with prostate SBRT outside trial.
• New 🌰 Prostate · 2026-07-19
  TROG 08.03 RAVES QOL Substudy
  Severe urinary leakage 16% vs 2% at 5yr with aRT vs no RT; timing of salvage RT unrelated to QOL.
• New 🚀 Practice-changing 🌰 Prostate · 2026-07-15
  STAMPEDE (abiraterone ± enzalutamide, high-risk non-metastatic)
  6yr MFS 82% vs 69%, HR 0·53 (0·44–0·64), adding 2yr abiraterone to ADT+RT; enzalutamide adds nothing.
• New 🫁 Thoracic / Lung · 2026-07-14
  Consolidative TRT + Atezolizumab Maintenance in ES-SCLC
  Primary EP missed: mOS 6.7 vs 13.4mo (HR 1.55, P=.34) with consolidative 30Gy/10fx; trial halted for fatal SAEs.
• New 🧠 CNS · 2026-07-13
  EANO Consensus Statement on Radiation Necrosis
  Delphi consensus: 53/57 statements reached ≥80% agreement across 20 experts; perfusion MRI + amino acid PET preferred, bevacizumab for steroid-refractory RN.
• New 🎀 Breast · 2026-07-09 ASTRO Annual Meeting 2024
  SUPREMO
  Editorial critique: chest-wall-only RT cut 10yr CW recurrence 1.1% vs 2.5% (HR 0.45) but RNI was prohibited.
• New 🌰 Prostate · 2026-07-09 ASTRO Annual Meeting 2024
  ASTRO 2024: SBRT for Unfavorable Intermediate-Risk Prostate Cancer
  Conference education session on SBRT for UIR prostate: 5 fractions over 1-2wks, 1-2% bothersome toxicity vs 10-30% with 45-fraction 2D era.
• New 🌰 Prostate · 2026-07-09 ASTRO Annual Meeting 2024
  HYDRA
  No PFS difference for either isodose (HR 0.92) or dose-escalated MHFRT (HR 0.94), but escalation raises late G2+ GI (OR 1.48).
• New 👄 Head & Neck · 2026-07-08 ASTRO Annual Meeting 2025
  ESTRO OCSCC Post-op CTV Delineation Guidelines
  First ESTRO guideline for post-op CTV delineation in oral cavity SCC: GTV-P pre-op + 10 mm composited with surgical defect/flap + 5 mm.
• New 🌰 Prostate · 2026-07-08 ASTRO Annual Meeting 2025
  NRG-GU005 (quality of life)
  Fewer MCID declines with SBRT at 1yr bowel (33% vs 46%, p=0.002) and sexual (34% vs 44%, p=0.026).
• New 🌰 Prostate · 2026-07-08 ASTRO Annual Meeting 2025
  10-yr SBRT Survival/Toxicity (Meier et al.)
  10-yr RFS 90% overall (94% LR, 86% IR) with 40 Gy/5 fx; grade 3 late toxicity 1.4-1.5%, no grade 4-5.
• New 🌰 Prostate · 2026-07-08 ASTRO Annual Meeting 2025
  American Radium Society AUC: Local Intraprostatic Recurrence
  Severe GU toxicity 20% after salvage RP vs 5.6% SBRT, 9.6% HDR: panel prefers biopsy-confirmed reirradiation.
• New 🚀 Practice-changing 🎀 Breast · 2026-07-07
  SUPREMO
  10yr OS 81.4% vs 81.9% (HR 1.04, 0.82-1.30, p=0.80): PMRT omission safe in intermediate-risk pN0-pN1 post-mastectomy.
• New 🌰 Prostate · 2026-07-07
  ARTO
  Adding SBRT to all met sites improved OS: median NR vs 50 mo, HR 0.55 (0.33-0.92), p=0.021 in omCRPC.
• New 🧠 CNS · 2026-07-07
  EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU
  Mature phase III: RT (50.4Gy/28fx) vs dose-dense TMZ in high-risk WHO grade 2 LGG, no PFS or OS difference in any molecular subtype.
• New 🟡 Hepatobiliary · 2026-07-01
  RTOG 1112
  mOS 15.8 vs 12.3mo, HR 0.77 (90% CI 0.59-1.01), 1-sided P=.06; adjusted HR 0.72, P=.04; PFS HR 0.55.
• New 👄 Head & Neck · 2026-07-01
  ReCOG HNSCC Reirradiation Consensus
  International consensus: 24 of 31 statements reached ≥85% agreement; elective nodal irradiation not recommended (100%), definitive CTV = GTV + 5 mm.
• New 💧 Bladder · 2026-06-29 ASTRO Annual Meeting 2025
  BART
  2yr LRFFS 87.1% vs 76.0% with adjuvant pelvic RT after cystectomy, HR 0.43 (0.20-0.96), p=0.04; OS unchanged.
• New 🌰 Prostate · 2026-06-25
  ENZARAD (ANZUP 1303)
  8yr MFS 74% vs 72%, HR 0.88 (0.67-1.15), p=0.34: enzalutamide added to 2yr ADT + RT missed its primary endpoint.
• New 🌀 GI Lower · 2026-06-21
  ARS Appropriate Use Criteria: Locoregionally Recurrent Rectal Cancer
  Updated ARS appropriate use criteria for LRRC, built on 116 references (10 randomized phase 2/3), reaffirming combined-modality therapy toward R0 resection.
• New 🌰 Prostate · 2026-06-18
  PRIMARY2
  csPCa 12% vs 16% (difference -3.7%, 95% CI -8.9 to 1.5, p=0.0093 non-inferiority), and PSMA-PET avoided biopsy in 49%.
• New 💧 Bladder · 2026-06-17
  INDIBLADE
  2yr bladder-intact EFS 78% (0.67-0.9) after induction ipi/nivo then chemoRT in cT2-4aN0-2 MIBC; 2yr OS 96% (0.91-1).
• New 🦴 Sarcoma · 2026-06-16
  DOREMY
  5yr LRFS 97.4% after 36Gy/18fx preop RT in myxoid liposarcoma, wound complications 21%, median f/u 66.4mo.
• New 🌰 Prostate · 2026-06-16
  REVELUTION
  Adjusted 12-mo total plaque volume rose 68.9 mm³ more with leuprolide vs relugolix in men getting prostate RT.
• New 👄 Head & Neck · 2026-06-15
  KEYNOTE-689 vs NIVOPOSTOP
  Educational round-up contrasting perioperative pembro vs postoperative nivo in resectable LA-HNSCC; 3yr DFS ~63% vs 53% cited for NIVOPOSTOP.
• New 🎀 Breast · 2026-06-14
  GEC-ESTRO Breast Cancer Working Group APBI patient selection recommendations
  Updated APBI selection criteria collapse to two groups (low-risk eligible, high-risk contraindicated), widening eligibility to pT1-2 ≤30mm, pN1mi, any histology.
• New 🌰 Prostate · 2026-06-12
  ARTO
  Adding SBRT to abiraterone in oligometastatic CRPC: biochemical response 92% vs 68.3%, OR 5.34; PFS HR 0.35.
• New 🌰 Prostate · 2026-06-12
  WOLVERINE
  IPD meta-analysis of 6 randomised phase 2 trials, 472 pts: MDT improved PFS (HR 0.44, 0.35-0.56), OS non-significant (HR 0.63, 0.39-1.00, p=0.051).
• New 🌰 Prostate · 2026-06-12
  ORIOLE
  6-mo composite progression 19% vs 61% with SABR (P=.005); mPFS not reached vs 5.8 mo, HR 0.30.
• New 🌰 Prostate · 2026-06-12
  EAU 2026: What Evidence Do We Have from Intensification with SBRT?
  Session review of MDT in oligometastatic prostate: ARTO the only randomised OS signal; no effect sizes reported in source.
• New 🌰 Prostate · 2026-06-12
  RADIOSA
  cPFS 32.2 vs 15.1 mo, HR 0.43, adding 6 months of ADT to ablative SBRT in metachronous oligorecurrence.
• New 🍽️ GI Upper · 2026-06-10
  RTOG 0848
  Adjuvant CXRT after 6 cycles gemcitabine-based chemo missed OS (HR 0.96), but node-negative pts gained: 5yr OS 48.1% vs 28.6%.
• New 🧠 CNS · 2026-06-09
  NRG Oncology RTOG 0539
  10-yr PFS 85.2% observed low-risk, 72.2% intermediate-risk at 54 Gy, 42.5% high-risk at 60 Gy.
• New 🧠 CNS · 2026-06-09
  FIRESTORM
  5-yr PFS 65.8% vs 38.8% with dose-escalated postop RT (BED ≥79.2 Gy) in high-risk meningioma; MVA HR 0.40.
• New 🎀 Breast · 2026-06-09
  RAPCHEM (BOOG 2010-03)
  10yr locoregional recurrence 2.9% (24/838) with response-adapted RT after neoadjuvant chemo; 2.4% in the RT-omission-eligible low-risk group.
• New 🌰 Prostate · 2026-06-04 ASCO Annual Meeting 2026
  MROQC ADT Practice Patterns
  67.0% of 553 high-risk pts got guideline-concordant ADT (≥18mo); ARPI use 23.2% among STAMPEDE-eligible post-publication.
• New 👄 Head & Neck · 2026-06-04 ASCO Annual Meeting 2026
  AREST
  3yr LRFS 89.2% vs 80.9% with adjuvant RT after adequate resection of intermediate-risk pT1-2N0 OSCC; HR 0.52, no OS gain.
• New 🌀 GI Lower · 2026-06-02 ASCO Annual Meeting 2026
  mRCAT-III
  pCR 61.0% vs 28.6% (P<0.0001) when elective nodal RT was omitted and tislelizumab added in pMMR/MSS LARC.
• New 🫁 Thoracic / Lung · 2026-06-02 ASCO Annual Meeting 2026
  LBA8005: Concurrent Thoracic RT + Chemoimmunotherapy in ES-SCLC
  mOS 10.0 vs 11.8 mo, HR 1.14 (0.84-1.56), p=0.40: adding 30Gy/10fx consolidative TRT to chemo-IO did not improve survival.
• New 🎀 Breast · 2026-06-02 ASCO Annual Meeting 2026
  RT + Systemic Therapy: What to Continue vs Hold (Speers)
  ASCO 2026 education session slides triaging concurrent systemic agents with breast/CW + RNI into continue, caution, and hold/sequence.
• New 🌀 GI Lower · 2026-06-01 ASCO Annual Meeting 2026
  ctDNA and Local Regrowth/Distant Mets in Nonoperative Rectal Cancer
  ctDNA sensitivity for local regrowth only 41% (12/29), specificity 94%; distant mets sensitivity 74%, specificity 97%.
• New 🫁 Thoracic / Lung · 2026-06-01 ASCO Annual Meeting 2026
  DeLLphi-304
  Post hoc CNS analysis: median CNS PFS NE vs 7.2mo, HR 0.54 (0.39-0.75) favoring 2L tarlatamab in SCLC.
• New 🌀 GI Lower · 2026-05-31
  MIRACLE-2
  ORR 68%, mOS 23.2mo with upfront HFRT/SBRT then chemo + tislelizumab in MSS unresectable metastatic rectal ca; 18% reached NED.
• New 🌰 Prostate · 2026-05-31
  COMPPARE
  Proton vs IMRT: no difference in bowel urgency (5.7% vs 6%), ≥G2 GI toxicity (5.2% vs 5.6%), or 3yr disease control.
• New 🌰 Prostate · 2026-05-31
  CAN-2409
  DFS median NR vs 86.1mo, HR 0.70 (0.52-0.94), p=0.016, adding intraprostatic gene therapy to definitive EBRT.
• New 🌰 Prostate · 2026-05-31
  PROTEUS
  Most distant metastases were PSMA PET-detected (53.0% apalutamide, 60.7% comparator); no EFS or MFS effect size in source.
• New 🚀 Practice-changing 🍽️ GI Upper · 2026-05-31
  RASolute 302
  mOS 13.2 vs 6.6mo, HR 0.40 (0.30-0.54), P<0.001 for daraxonrasib vs chemo in RAS G12 2L metastatic pancreatic.
• New 🫁 Thoracic / Lung · 2026-05-31
  OCEANUS
  Sequential iRT beat concurrent for OS in newly diagnosed advanced NSCLC (20.3 vs 16.0 mo, aHR 0.68, P=.045); territory-wide cohort.
• New 💧 Bladder · 2026-05-30 ASCO Annual Meeting 2026
  RAD-IO
  12-mo DFS 40/50 (80%, 95% CI 0.67-0.89) with durvalumab added to 5FU/MMC chemoRT, clearing the pre-set GO bar (≥75%).
• New 💧 Bladder · 2026-05-30 ASCO Annual Meeting 2026
  Management After pCR in MIBC (Panel)
  Panel review: sandwich immunotherapy regimens continue planned adjuvant therapy regardless of pCR, with de-escalation still unanswered.
• New 💧 Bladder · 2026-05-30 ASCO Annual Meeting 2026
  Living Longer, Living Better (GU Discussant)
  ASCO 2026 GU discussant on curing more while preserving organ, bladder, and kidney function across MIBC, RCC, and ctDNA selection.
• New 🌰 Prostate · 2026-05-30 ASCO Annual Meeting 2026
  A-DREAM
  41% treatment-free with eugonadal T at 18mo after stopping ADT+ARPI in responding mHSPC (80% CI 33.1-48.9%, one-sided p 0.0249).
• New 🌰 Prostate · 2026-05-30 ASCO Annual Meeting 2026
  Precision Oncology: New Biomarkers in GU Practice (Panel)
  Discussant session on biomarker readiness in prostate cancer; discordance between Decipher and clinical risk emerged in 24% of events.
• New 🌰 Prostate · 2026-05-30 ASCO Annual Meeting 2026
  ENZAMET + Decipher
  Decipher >0.85 predicts docetaxel benefit in mHSPC on ADT+enza: HR(OS) 0.75 (0.43-1.33) vs 1.94 (0.95-3.96) if ≤0.85, interaction p=0.04.
• New 🌰 Prostate · 2026-05-30 ASCO Annual Meeting 2026
  ARACOG (AFT-47)
  Enzalutamide MCCD decline -36.1 vs -15.8 for darolutamide at 24wks (P=0.009) in randomized phase 2, N=111.
• New 🚀 Practice-changing 🌰 Prostate · 2026-05-30 ASCO Annual Meeting 2026
  TALAPRO-3
  3yr rPFS 77% vs 56%, stratified HR 0.48 (0.36-0.65), p<0.001, adding talazoparib to enzalutamide in HRR-deficient mCSPC.
• New 🌰 Prostate · 2026-05-30 ASCO Annual Meeting 2026
  Clinico-transcriptomic Risk Stratification (Abstract 5000)
  ~¼ of NCCN ≥HR pts carry discordant clinical vs biomarker risk; 22-gene GC independently prognostic for MFS, DM, OS.
• New 🎀 Breast · 2026-05-30 ASCO Annual Meeting 2026
  PREPEC
  Pre-pectoral implant improved 24-mo BREAST-Q physical well-being (chest) by 4.8 points, but implant loss 21.1% vs 14.5%.
• New 🧠 CNS · 2026-05-30 ASCO Annual Meeting 2026
  ROADS
  Surgical bed recurrence 1% with GammaTile brachytherapy vs 12% post-op SRS in resected brain mets >2cm, N=230.
• New 🫁 Thoracic / Lung · 2026-05-30 ASCO Annual Meeting 2026
  CHRYSALIS-2
  Median OS 41.0 mo (95% CI 27.7-NE) with 1L amivantamab + lazertinib in atypical EGFR-mutant NSCLC, single-arm n=49.
• New 🫁 Thoracic / Lung · 2026-05-30 ASCO Annual Meeting 2026
  ESAONA
  iORR 95.5% vs 79.6% (p=0.0004) and intracranial PFS HR 0.46 favoring asandeutertinib in 1L EGFR-mutant NSCLC with brain mets.
• New 🫁 Thoracic / Lung · 2026-05-30 ASCO Annual Meeting 2026
  OptiTROP-Lung05
  mPFS NR vs 5.7mo, HR 0.35 (0.26-0.47) for sac-TMT + pembro in 1L PD-L1+ NSCLC.
• New 🍽️ GI Upper · 2026-05-30 ASCO Annual Meeting 2026
  Neo-CRAG
  Adding preop 45Gy/25fx to periop XELOX raised 3yr DFS 55.6% vs 42.4%, HR 0.750; mOS 67.5 vs 37.6mo.
• New 🤝 Supportive / QoL · 2026-05-30 ASCO Annual Meeting 2026
  SPIN Score (Celiac Plexus Radiosurgery)
  Post-hoc predictors of pain response after celiac SRS: response 32% / 53% / 89% by 0 / 1 / 2 SPIN points.
• New 🧠 CNS · 2026-05-29 ASCO Annual Meeting 2026
  Wait or Treat (NCT05236946)
  Upfront cranial RT cut intracranial progression (sub-HR 0.35, 0.21-0.59, p<0.001) but 2y OS favored delayed RT, 48% vs 60%.
• New 🚀 Practice-changing 🎀 Breast · 2026-05-27
  SENOMAC
  5yr RFS 89.7% vs 88.7% omitting completion ALND, HR 0.89 (0.66-1.19), noninferior in 1-2 SLN macromets.
• New 🫁 Thoracic / Lung · 2026-05-26
  SWOG/NRG S1914
  OS HR 1.15 (0.65-2.01), p=0.63: atezolizumab added to SBRT failed, with more local failures (13% vs 7%) and G≥3 AEs (12% vs 2%).
• New 🌐 Lymphoma · 2026-05-22
  EORTC Cutaneous Lymphoma Tumour Group RT Recommendations
  Expert-opinion dose recommendations consolidating reduced-dose RT (4-12 Gy) across cutaneous lymphoma subtypes; no randomised trials underpin any of it.
• New 🎀 Breast · 2026-05-22
  DBCG IMN2
  IMNI cut 15y mortality: OS 65.0% vs 60.8%, adjusted HR 0.85 (0.76-0.94), p=0.0016, in 4541 node-positive pts.
• New 🌰 Prostate · 2026-05-22
  PEACE V-STORM
  4yr MFS 76% vs 63% with elective pelvic nodal RT over MDT, HR 0·62 (80% CI 0·44-0·86), p=0·063.
• New 🎀 Breast · 2026-05-21
  SWOG S1007
  5yr LRR 0.85% with RNI vs 0.55% without after BCS+RT in RS≤25 N1 disease; IDFS unchanged by RNI.
• New 🎀 Breast · 2026-05-21
  EORTC 22922/10925
  20yr OS 61.0% vs 61.8% (HR 1.00, p=.967): IM-MS nodal RT cut breast cancer mortality but added non-cancer deaths.
• New 💧 Bladder · 2026-05-21
  Bladder Adjuvant Radiotherapy
  2yr LRFS 87.1% vs 76.0% with adjuvant pelvic IMRT after RC, HR 0.43 (0.20-0.96), P=.04; DFS/BCSS/OS not significant.
• New 🎀 Breast · 2026-05-20
  Proton vs Photon PMRT Capsular Contracture
  2yr CC 50% with proton+DTI vs 12% photon+TE/I; proton HR 2.3 univariate, 1.76 (0.93-3.32) multivariable, ns.
• New 🎀 Breast · 2026-05-20
  NRG/RTOG 9804 + E5194 combined analysis
  15yr IBR 11.4% vs 19.0% with tamoxifen after lumpectomy alone in good-risk DCIS; MVA HR 0.54 for any IBR.
• New 🫁 Thoracic / Lung · 2026-05-20
  High-dose hyperfractionated SIB RT vs standard-dose RT (limited-stage SCLC)
  mOS 60.7 vs 39.5mo, HR 0.55 (0.37-0.72), p=0.003 for 54Gy SIB vs 45Gy BID, no added toxicity.
• New 🌰 Prostate · 2026-05-19 ESTRO Congress 2026
  ePLND vs PSMA-PET staging (AUA2026 round-up)
  AUA2026 round-up: PSMA-PET NPV ~96% may allow PLND omission in intermediate risk; 47.7% of nodal mets sit outside ePLND template.
• New 💧 Bladder · 2026-05-19 ESTRO Congress 2026
  Bladder-preserving TMT multicenter analysis (URONCOR)
  CLR 63.7% in a 369-pt Spanish TMT cohort; salvage cystectomy 9.7%, image-guidance quality and 5-FU-based CRT predicted local response.
• New 🫁 Thoracic / Lung · 2026-05-19 ESTRO Congress 2026
  Single-fraction SABR pooled analysis, 1687 pts
  Local control 90-93% at 2yr and G3+ AEs 2.9% across 1687 single-fraction SABR pts at 3 centres.
• New 🌀 GI Lower · 2026-05-18 ESTRO Congress 2026
  OPERA
  W14 clinical response (DRE+rectoscopy) identified 76% good responders; 5yr organ preservation 75% A vs 83% B, p=0.24.
• New 🌰 Prostate · 2026-05-18 ESTRO Congress 2026
  HEAT
  Interim: BF 7% vs 7.4% at 4.25y, p-non-inferiority 0.007, 5-fx SBRT non-inferior to 26-fx IMRT with ADT allowed.
• New 👄 Head & Neck · 2026-05-18 ESTRO Congress 2026
  TORPEdO
  No mean UW-QoL physical composite difference IMPT vs IMRT at 3/12/24 mo post RT, 205 pts.
• New 👄 Head & Neck · 2026-05-18 ESTRO Congress 2026
  INRT-AIR & DARTBOARD pooled analysis
  5yr solitary elective nodal recurrence 0% with ENI omission in HNSCC; 5yr OS 87%, PFS 74%, n=117.
• New 🚀 Practice-changing 🎀 Breast · 2026-05-18 ESTRO Congress 2026
  NRG/RTOG 1005
  7yr IBR 2.6% concurrent vs 2.2% sequential, HR 1.31 (90% CI 0.84-2.04), noninferior, one shorter course.
• New 🟡 Hepatobiliary · 2026-05-18 ESTRO Congress 2026
  Multinational HCC EBRT IPD Cohort
  Median OS 6.8y BCLC-0 and 4.6y BCLC-A across 4,913 EBRT-treated HCC pts, comparable to resection and ablation.
• New 🎯 Oligometastatic / Mets · 2026-05-18 ESTRO Congress 2026
  EXTEND
  PFS HR 0.54 (0.41-0.72), p<0.001 for MDT added to SOC across 6 oligometastatic baskets; RT delivered 98% of MDT.
• New 🫘 Kidney · 2026-05-18 ESTRO Congress 2026
  FASTRACK II
  100% freedom from local progression at 36, 60, and 84mo after single-fraction 26Gy or 42Gy/3fx SABR in inoperable primary RCC.
• New 🌰 Prostate · 2026-05-17 ESTRO Congress 2026
  POP-RT vs PEACE-2
  WPRT bFFS HR 0.50 (POP-RT) vs bPFS HR 0.97 (PEACE-2); pelvic RT benefit vanishes with 3yr ADT, PSMA staging.
• New 🌰 Prostate · 2026-05-17 ESTRO Congress 2026
  PRIME
  Interim: acute grade ≥2 GU ~5.4% vs ~4.0% (p=0.59) for 5-fx SBRT vs 25-fx, both with whole-pelvis RT; BFFS immature.
• New 🌰 Prostate · 2026-05-17 ESTRO Congress 2026
  PIVOTALboost
  Adding pelvic nodal IMRT to a focal prostate boost in 20fx raised early bowel toxicity only; 2yr G2+ rates similar across arms.
• New 🌰 Prostate · 2026-05-17 ESTRO Congress 2026
  PACE-NODES
  CTCAE G2+ GI toxicity 28% vs 21% with added pelvic nodal SBRT; no GU difference, symptoms resolved by 12wk.
• New 🌰 Prostate · 2026-05-17 ESTRO Congress 2026
  PEACE-2
  cPFS HR 0.81 (0.63-1.03), p=0.088: pelvic RT over prostate-only missed its primary endpoint in very-high-risk N0M0.
• New 🎀 Breast · 2026-05-17 ESTRO Congress 2026
  OLIGOMA
  mPFS 35.8 vs 20.4mo, HR 0.48 (0.25-0.91) p=0.021 with ablative RT to all lesions in oligometastatic breast.
• New 🎀 Breast · 2026-05-17 ESTRO Congress 2026
  APBI-IMRT Florence
  15-yr IBTR 7.7% APBI vs 4.2% WBI, HR 1.57 (0.82-3.04) p=0.17; excess driven by new ipsilateral primaries, not true local relapse.
• New 🎀 Breast · 2026-05-17 ESTRO Congress 2026
  EORTC IM-MS (22922/10925)
  20yr OS 61.0% vs 61.8%, HR 1.00 (0.90-1.10), P=0.967: the 15yr breast-cancer mortality benefit is erased by non-BCM.
• New 🎀 Breast · 2026-05-17 ESTRO Congress 2026
  DBCG RT Natural
  5yr invasive LR 1.5% with PBI vs 9.8% randomised no-PBI vs 8.2% self-selected no-PBI at 4yr median f/u.
• New 🎀 Breast · 2026-05-17 ESTRO Congress 2026
  IMPORT HIGH
  10yr IBTR 3.7% with 48Gy/15F SIB vs 3.5% with 40Gy/15F + 16Gy/8F sequential; 53Gy/15F higher at 5.5%.
• New 🎀 Breast · 2026-05-17 ESTRO Congress 2026
  DBCG HYPO
  10yr grade 2-3 breast induration 24.7% (50Gy) vs 19.5% (40Gy), HR 0.76 (0.62-0.92), p=0.005, no recurrence penalty.
• New 🎀 Breast · 2026-05-17 ESTRO Congress 2026
  HypoG-01
  118 first events over 4.8yr median f/u; 67% of LRR sites in-volume, patterns comparable across 40Gy/15fx and 50Gy/25fx.
• New 🎀 Breast · 2026-05-17 ESTRO Congress 2026
  Tumour bed boost after BCS+WBRT (Dutch cohort)
  10yr IBTR 1.2% with 0-2 risk factors regardless of boost, supporting boost omission in the modern systemic era.
• New 🎯 Oligometastatic / Mets · 2026-05-17 ESTRO Congress 2026
  OligoCare
  Real-world SABR local failure 5.0% at 1yr, 11.4% at 3yr across 2447 pts / 3533 lesions; CRC worst at 19.6%.
• New 🫘 Kidney · 2026-05-17 ESTRO Congress 2026
  RCC SBRT (5-year local control)
  100% local control at 5 years for RCC treated with SBRT, per a conference slide; no N, dose, or CI in source.
• New 👄 Head & Neck · 2026-05-17 ESTRO Congress 2026
  DIREKHT
  De-escalated post-op HNSCC RT: contralateral neck sparing and primary CTV to 56 Gy in selected pts; no outcome numbers in source tweet.